The choice of model organism is central to the study’s design. The team used Drosophila melanogaster flies genetically modified to express human amyloid-beta 42, the sticky peptide that aggregates into the plaques characteristic of Alzheimer’s disease. Although flies are distant from humans on the evolutionary tree, they share a remarkable proportion of their genes with people, and many of the molecular pathways implicated in neurodegeneration, including oxidative stress responses, cholinergic signalling, and tau phosphorylation cascades, are conserved. Fruit flies also live for only weeks, which means researchers can observe the full course of a neurodegenerative process and test interventions across the lifespan in a matter of days, something impossible in rodent or human studies. In this experiment, the Alzheimer-model flies were treated with the Caralluma extract for fourteen days before being assessed.

The behavioural results were the most visible evidence of benefit. Flies carrying the human amyloid-beta 42 gene typically show progressive deterioration in climbing ability, a standard measure of locomotor function in fly neurodegeneration research, as well as impaired grooming and deficits in learning assays. Treated flies performed significantly better across these measures and lived longer than their untreated counterparts. The researchers used an aversive phototaxis suppression assay to probe learning and memory, a test that measures a fly’s ability to suppress its natural attraction to light when that light is paired with an unpleasant stimulus. Improved performance in this assay suggests that the extract protected cognitive function, not merely motor capacity, although the authors are careful to frame these as preliminary findings in an invertebrate system.

Beneath the behavioural improvements, the biochemical data pointed to a familiar theme in neurodegeneration research: oxidative stress. The brains of Alzheimer-model flies suffer from an excess of reactive oxygen species that damage lipids, proteins, and DNA. The team measured malondialdehyde, a breakdown product of lipid peroxidation that serves as a marker of oxidative damage, and found it reduced in treated flies. At the same time, levels of the antioxidants glutathione and superoxide dismutase, two of the cell’s primary defences against oxidative injury, were increased. This shift in the balance between oxidative damage and antioxidant capacity is consistent with a neuroprotective effect and aligns with the known chemistry of many plant-derived polyphenols, which can act as antioxidants directly and can also induce the cell’s own antioxidant defence systems.

Perhaps the most pharmacologically interesting finding concerned acetylcholinesterase, the enzyme that breaks down the neurotransmitter acetylcholine. Cholinergic neurons in the brain are among the earliest casualties of Alzheimer’s disease, and the loss of acetylcholine contributes substantially to the memory impairment that defines the condition. Four of the currently approved Alzheimer’s drugs, including donepezil and galantamine, work by inhibiting acetylcholinesterase to keep acetylcholine available for longer in the synaptic cleft. In the treated flies, acetylcholinesterase levels were significantly reduced, suggesting that the extract may reproduce, at least partially, the mechanism of existing symptomatic therapies through a natural product mixture.

The molecular layer of the study focused on tau, the microtubule-associated protein whose pathological tangles inside neurons form the second hallmark lesion of Alzheimer’s disease alongside amyloid plaques. Quantitative analysis showed that the fly equivalent of the tau gene, dTau, was downregulated in extract-treated flies compared with untreated Alzheimer-model flies. Because tau pathology correlates more closely with cognitive decline than amyloid burden in human disease, any intervention that reduces tau expression or the signalling that drives tau phosphorylation attracts considerable attention. The researchers propose that the extract may be acting upstream of tau through pathways that connect amyloid toxicity to tau dysfunction.

To explore those upstream connections, the team turned to molecular docking, a computational technique that predicts how well small molecules fit into the binding pockets of target proteins. They focused on two enzymes with central roles in Alzheimer’s biology: glycogen synthase kinase-3, known as GSK3, and beta-secretase 1, known as BACE1. GSK3 is the major kinase that phosphorylates tau in the brain, promoting its aggregation into tangles, and it also participates in inflammatory and apoptotic signalling. BACE1 is the enzyme that performs the first cut in the production of amyloid-beta from its parent protein, making it a prime drug target for reducing amyloid generation. Docking simulations suggested that several phytochemicals present in the extract interact favourably with both enzymes, with catechin, a flavonoid found in many plants, showing the most promising predicted binding profiles against GSK3 and BACE1 alike.

The authors are explicit that docking is a hypothesis-generating tool rather than proof of mechanism. Predicted binding energies do not confirm that catechin or any other constituent of the extract actually inhibits GSK3 or BACE1 inside a living organism, and the extract is a complex mixture whose active components and their concentrations remain to be fully characterised. The study also did not directly measure amyloid-beta deposition or tau phosphorylation in the fly brains, so the link between the observed gene expression changes and the actual pathological lesions of Alzheimer’s disease remains to be established. Direct target validation, the authors note, together with assessment of amyloid and tau pathology and studies in mammalian models, will be required before any therapeutic relevance can be claimed.

Even with those caveats, the study fills a genuine gap. Caralluma dalzielii has a long history of traditional use for neurological complaints in the region where it grows across the Sahel and West Africa, yet it had never previously been evaluated in an experimental model of Alzheimer’s disease. Its close relative Caralluma fimbriata has been studied mainly for appetite suppression, and the genus as a whole remains underexplored relative to its chemical richness. Plants in this group produce an array of pregnane glycosides, flavonoids, and other secondary metabolites, and the new findings suggest that some of these compounds may act on multiple nodes of the Alzheimer’s disease network simultaneously, a polypharmacology that single-target drugs often lack.

The research also demonstrates the continuing value of the humble fruit fly in early-stage drug discovery. A complete behavioural, biochemical, and molecular evaluation of a natural product extract was accomplished in a model system that is inexpensive, rapid, and free of the ethical and logistical constraints of vertebrate studies, supported by funding from Nigeria’s TETFund institutional research programme. For a disease that affects tens of millions of people worldwide and for which approved therapies offer only modest symptomatic benefit, the pipeline of candidate compounds needs every accessible entry point. The Nigerian team’s results do not amount to a treatment, and no one should interpret them as a recommendation to seek out the plant itself. What they provide is a rigorous preliminary signal, generated through a transparent and reproducible workflow, that Caralluma dalzielii deserves a place in the queue of natural products being screened for Alzheimer’s drug discovery. If catechin and its neighbours in the extract can be isolated, validated against GSK3 and BACE1 in vitro, and tested in mammalian models of the disease, this Sahelian succulent may yet contribute more to modern medicine than its traditional reputation alone ever suggested.

Subject of Research: Neuroprotective effects of Caralluma dalzielii extract in a transgenic Drosophila model of Alzheimer's disease

Article Title: Targeting Alzheimer’s disease pathways with Caralluma dalzielii: behavioural, biochemical, and molecular evidence from a transgenic Drosophila melanogaster model

Article References: Ugwah-Oguejiofor, C. J., Hassan, E., Yakubu, D., Ahmed, A. H., Almustapha, Z., & Imam, M. U. (2026). Targeting Alzheimer’s disease pathways with Caralluma dalzielii: behavioural, biochemical, and molecular evidence from a transgenic Drosophila melanogaster model. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05637-3

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05637-3

Keywords: Caralluma dalzielii, Alzheimer's disease, Drosophila melanogaster, amyloid-beta 42, tau, GSK3, BACE1, acetylcholinesterase, oxidative stress, catechin, phytochemicals, molecular docking